What stage does OCCIDENT invest at?

OCCIDENT invests at Seed stage.

What check size does OCCIDENT write?

InvestorMatch does not have a recorded check size for OCCIDENT. Its stage focus (Seed) is the best available signal for round size.

What sectors does OCCIDENT invest in?

OCCIDENT invests in Healthcare, Security.

What has OCCIDENT invested in recently?

OCCIDENT has 24+ portfolio companies, including Immitra Bio, Lymphatica, Altavo, Chipmetrics, ReCatalyst.

How much capital does OCCIDENT manage?

OCCIDENT manages approximately $500M in assets under management.

OCCIDENT — Seed VC Firm

Q: Who are the partners at OCCIDENT?

Partners at OCCIDENT include Michael Pauer (Chief Investment Officer), Paul Sunzenauer (Investment Manager).

GermanyProfile updated October 2026Website

OCCIDENT is a Seed venture capital firm based in Germany investing in Healthcare, Security. The firm has 24 portfolio companies in our records.

Portfolio: 24 companies on record
Partners: 2 listed
AUM: $500M
Stage: Seed
Sectors: Healthcare, Security
HQ: Germany
Check size: Not in our records

Last verified: 2026-10-30

How to approach: warm intro preferred

Stage

Seed

AUM

$500M

Portfolio

24+ companies

Team

2 partners

Investment Thesis

OCCIDENT invests in industrial biotech and has explicitly backed a peptide-production company at seed stage. The peptide and biotech orientation is highly relevant for a bioactive peptide startup, even though the use case is adjacent to beauty rather than therapeutics.

How OCCIDENT invests

OCCIDENT is a vc firm based in Germany. The firm invests at the Seed stage, with a focus on Healthcare, Security.

OCCIDENT manages approximately $500M in assets. Our records include 3 funds raised by the firm.

OCCIDENT has backed 24 companies in our records, including Immitra Bio, Lymphatica, Altavo.

Partners & Team

Michael Pauer

Chief Investment Officer

Paul Sunzenauer

Investment Manager

Industry Focus

Invests In

Healthcare

Security

Funds

Fund III

$250M2023

actively investing

Fund II

$150M2021

actively investing

Fund I

$100M2019

fully deployed

Recent Activity

Raised Fund III ($250M)

2023 · fund records

Raised Fund II ($150M)

2021 · fund records

Raised Fund I ($100M)

2019 · fund records

Portfolio Companies (24)

Other

Immitra Bio

Lifesciences

Neue Plattform für die In-vivo-Gentherapie bei seltenen genetischen Erkrankungen.

Lymphatica

Lifesciences

Medizintechnikunternehmen zur Behandlung von Lymphödemen.

Altavo

Lifesciences

MedTech-Startup zur Verbesserung der Rehabilitation von stimmlosen Menschen.

Chipmetrics

Industrial Tech

Entwicklung und Produktion innovativer Messchips und Wafer für die Halbleiterindustrie.

ReCatalyst

Industrial Tech

Entwicklung innovativer Katalysatoren für Brennstoffzellen.

EBAMed

Lifesciences

Medizintechnikunternehmen im Bereich der Protonentherapie.

core sensing

Industrial Tech

Entwicklung innovativer Sensortechnologie für Maschinenbau.

Avelo

Lifesciences

Diagnostik-Startup zur Verbesserung der Diagnose von Atemwegsinfektionen.

hemotune

Lifesciences

Entwicklung einer Plattformtechnologie zur extrakorporalen Blutreinigung.

Algiax Pharmaceuticals

Lifesciences

Entwicklung innovativer Produkte zur Behandlung von Krankheiten mit hohem medizinischen Bedarf.

How to pitch OCCIDENT

•Raising at Seed? You're squarely in their sweet spot.
•Lead with your fit in Healthcare, Security — the sectors they actively back.
•warm intro preferred
•Address your outreach to a specific partner, such as Michael Pauer, Chief Investment Officer.
•A warm introduction beats a cold email. Get matched and request an intro.